A powerful new biochemical platform is fueling the study of a family of enzymes that are promising targets for cancer treatment. The new method provides a high-resolution view of how these enzymes, called lysine methyltransferases, selectively mark proteins with chemical tags that alter their function. Because of their central role in health and disease, proteins and the molecules that edit and interact with them often are targets for therapeutic development.